C Tural

Summary

Affiliation: Hospital Universitari Germans Trias i Pujol
Country: Spain

Publications

  1. ncbi Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients
    C Tural
    Clinical HIV Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    J Viral Hepat 10:118-25. 2003
  2. ncbi Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study
    C Tural
    HIV Clinical Unit, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Viral Hepat 14:704-13. 2007
  3. ncbi High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response
    R Paredes
    Retrovirology Laboratory Institut de Recerca de la SIDA Caixa, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
    J Acquir Immune Defic Syndr 22:132-8. 1999
  4. ncbi Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up
    E Negredo
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 4:23-8. 1999
  5. doi Estimated liver fibrosis and its impact on all-cause mortality of HCV-monoinfected and HCV/HIV-coinfected drug users
    A Sanvisens
    Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Curr HIV Res 9:256-62. 2011
  6. doi Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection
    A Sanvisens
    Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma, Barcelona, Spain
    J Viral Hepat 16:513-8. 2009
  7. doi Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors
    S Franco
    Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Viral Hepat 18:e578-82. 2011
  8. ncbi Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy
    A Tuldrá
    HIV Unit, Fundació Lluita SIDA and IrsiCaixa Retrovirology Laboratory, Germans Trias i Pujol University Hospital, Badalona, Spain
    J Acquir Immune Defic Syndr 25:221-8. 2000
  9. doi HIV-1 infected patients older than 50 years. PISCIS cohort study
    G Navarro
    Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, Spain
    J Infect 57:64-71. 2008
  10. doi Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline
    R SanMartin
    HIV Clinical Unit, Internal Medicine Service, University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    HIV Med 15:203-12. 2014

Detail Information

Publications31

  1. ncbi Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients
    C Tural
    Clinical HIV Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    J Viral Hepat 10:118-25. 2003
    ..73, 95% CI: 1.108-6.731) were associated with liver fibrosis. Hence ART should be a priority in HIV/HCV co-infected patients eligible for anti-HCV treatment as it is a protective factor for liver fibrosis...
  2. ncbi Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study
    C Tural
    HIV Clinical Unit, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Viral Hepat 14:704-13. 2007
    ..Despite the lack of benefit with this regimen, induction therapy with this schedule was safe and well tolerated in co-infected patients...
  3. ncbi High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response
    R Paredes
    Retrovirology Laboratory Institut de Recerca de la SIDA Caixa, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
    J Acquir Immune Defic Syndr 22:132-8. 1999
    ..This therapeutic efficacy is strongly implemented by a switch at the lower HIV-1 RNA levels...
  4. ncbi Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up
    E Negredo
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 4:23-8. 1999
    ..Maintenance of viral suppression was equivalent in both treatment groups. Additional data with longer follow-up are needed to confirm these results...
  5. doi Estimated liver fibrosis and its impact on all-cause mortality of HCV-monoinfected and HCV/HIV-coinfected drug users
    A Sanvisens
    Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Curr HIV Res 9:256-62. 2011
    ..Conclusions: Estimation of liver fibrosis using serum markers may help with clinical decisions to facilitate access to treatment of chronic hepatitis C in this population...
  6. doi Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection
    A Sanvisens
    Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma, Barcelona, Spain
    J Viral Hepat 16:513-8. 2009
    ..However, serum TGF-beta1 was not predictive of histological damage in co-infected individuals treated with HAART...
  7. doi Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors
    S Franco
    Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Viral Hepat 18:e578-82. 2011
    ..Our results also demonstrate that allele-specific PCR can be used to detect minor HCV NS3 protease resistant variants in pretreatment samples and to study in detail the evolution of mutant viruses during targeted antiviral therapy...
  8. ncbi Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy
    A Tuldrá
    HIV Unit, Fundació Lluita SIDA and IrsiCaixa Retrovirology Laboratory, Germans Trias i Pujol University Hospital, Badalona, Spain
    J Acquir Immune Defic Syndr 25:221-8. 2000
    ..Interventions to ensure a high level of adherence during a relatively long-term period of therapy are necessary...
  9. doi HIV-1 infected patients older than 50 years. PISCIS cohort study
    G Navarro
    Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, Spain
    J Infect 57:64-71. 2008
    ..The aim of this study is to characterize the ways in which older HIV-infected people differ from younger HIV-infected people...
  10. doi Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline
    R SanMartin
    HIV Clinical Unit, Internal Medicine Service, University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    HIV Med 15:203-12. 2014
    ..The aim of the study was to assess the progression of liver fibrosis in HIV/hepatitis C virus (HCV)-coinfected patients with no or mild-to-moderate fibrosis (stages F0-F2)...
  11. doi Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort
    C Manzardo
    Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Clin Microbiol Infect 19:646-53. 2013
    ..002; hazard ratio 1.83; 95% CI 1.25-2.68). Other independent risk factors for poorer outcome were baseline diagnosis of AIDS-defining lymphoma, age >35 years, and low CD4(+) count (<50 cells/μL)...
  12. doi Progression to AIDS or death in HIV-infected patients initiating cART with CD4<200 cells/µL: the role of CD4 and viral load changes during follow-up
    E Ferrer
    Hospital Universitari de Bellvitge, HIV Unit, Infectious Disease Service, Barcelona, Spain
    J Int AIDS Soc 15:18148. 2012
    ..VL at BL and mainly at follow up also played a role in patient outcome...
  13. doi Human papillomavirus 16 integration and risk factors associated in anal samples of HIV-1 infected men
    María Paz Cañadas
    Retrovirology Laboratory irsiCaixa Foundation, Barcelona, Spain
    Sex Transm Dis 37:311-5. 2010
    ..PATIENTS METHODS: This cross-sectional study included 269 HIV-infected males. Detection and typing of HPV-infection was done by multiplex PCR, and integration of HPV-16 by real-time PCR...
  14. ncbi Detection of hepatitis C virus antibodies in oral fluid specimens for prevalence studies
    V Gonzalez
    Microbiology Service, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    Eur J Clin Microbiol Infect Dis 27:121-6. 2008
    ..Using this assay, we observed an unadjusted anti-HCV prevalence of 78.6% among a population of intravenous drug users; when adjusted to account for assay sensitivity, this prevalence may be closer to 90%...
  15. doi High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study
    Anna Bonjoch
    Lluita contra la SIDA Foundation, University Hospital Germans Trias, Barcelona, Spain
    AIDS 24:2827-33. 2010
    ..Low bone mineral density (BMD) is an emerging metabolic condition in HIV-infected patients; however, data on progression of this disease are scarce...
  16. ncbi Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality
    Miriam J Alvarez-Martinez
    Hospital Clinic IDIBAPS, Universitat de Barcelona, Barcelona, Spain
    Diagn Microbiol Infect Dis 62:34-43. 2008
    ..03 and P < 0.001, respectively). The prevalence of DHPS mutants in Spain is low and is not associated with a worse outcome. Severe respiratory failure at admission is the strongest predictor of PCP outcome...
  17. pmc Impact of injecting drug use on the interruption of antiretroviral therapies
    R Muga
    Servicio de Medicina Interna, 4a planta, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Epidemiol Community Health 58:286-7. 2004
  18. ncbi [Use of non-occupational HIV post-exposure prophylaxis in Spain (2001-2005)]
    Nuria Vives
    Centro de estudios epidemiológicos sobre ITS SIDA de Cataluña CEEISCAT CIBER Epidemiología y Salud Pública CIBERESP, Hospital Universitario Germans Trias i Pujol, Carretera de Canyet s n, Badalona, Barcelona, Spain
    Enferm Infecc Microbiol Clin 26:546-51. 2008
    ..The aim of this study is to describe the characteristics of the persons exposed, types of exposures, antiretroviral treatment prescribed, and outcome of HIV infection in cases of non-occupational exposure in Spain...
  19. ncbi Hepatitis C virus NS3/4A quasispecies diversity in acute hepatitis C infection in HIV-1 co-infected patients
    M Nevot
    Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    J Viral Hepat 21:e19-28. 2014
    ..In addition, substantial genetic diversity was demonstrated in AHC. NS3/4A protease efficiency cleaving MAVS may be associated with virus transmission and response to pegIFN/RBV treatment...
  20. ncbi Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity
    E Abad
    Immunology Unit, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona, Spain
    J Autoimmun 10:175-80. 1997
    ..These results suggest that the autoantigens recognized by ANCA are different in patients with IBD from those with necrotising vasculitis...
  21. ncbi Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients
    C R Fumaz
    Universitat Autonoma de Barcelona, Barcelona, Spain
    AIDS Care 19:138-45. 2007
    ....
  22. ncbi Anti-intrinsic factor antibodies in systemic lupus erythematosus
    J Junca
    Service of Haematology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Lupus 2:111-4. 1993
    ..We conclude that IFAb may appear in SLE patients, although the cobalamin deficiency described in SLE seems to be due to the presence of IFAb in only a minority of cases...
  23. ncbi Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy
    M Jouan
    Department of Infectious Diseases, , Paris, France
    AIDS 15:23-31. 2001
    ..CONCLUSIONS: CMV retinitis maintenance therapy may be safely discontinued in patients with CD4 cell counts above 75 x 10(6) cells/l who have been taking HAART for at least 18 months...
  24. ncbi Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations
    V Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Viral Hepat 11:2-17. 2004
    ..These guidelines represent a comprehensive and updated overview on the management of hepatitis B and C in HIV-infected patients...
  25. ncbi Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade
    S Sauleda
    Blood Bank CTBT, Hospital Vall d Hebron, Spain
    Haemophilia 12:228-36. 2006
    ..In HIV HCV haemophiliacs, the cumulative probability of developing hepatotoxicity during follow-up is high and although in the most cases the toxicity is mild, fatal cases can occur...
  26. doi Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    J Acquir Immune Defic Syndr 48:324-33. 2008
    ..To investigate prevalence of transmitted drug-resistant human immunodeficiency virus (TDR) and factors associated with TDR and to compare virological and CD4 count response to combination antiretroviral therapy...
  27. ncbi Liver transplantation in HIV/hepatitis co-infection
    Jose M Miro
    Infectious Diseases Service, Hospital Clinic IDIBAPS, Villarroel, 08036 Barcelona, Spain
    J HIV Ther 12:24-35. 2007
    ..Finally, this field is evolving continuously and the indications for liver transplantation or the management of HCV co-infection may change in the future as more evidence becomes available...
  28. doi European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults
    J K Rockstroh
    Department of Medicine I, University of Bonn, Bonn, Germany
    HIV Med 9:82-8. 2008
    ..With the introduction of new agents for the treatment of hepatitis B and increased knowledge of how best to manage hepatitis C, an update of current guidelines for management of HBV and HCV coinfection with HIV is warranted...
  29. ncbi Severe Legionnaires' disease successfully treated with levofloxacin and azithromycin
    M L Pedro-Botet
    J Chemother 18:559-61. 2006
  30. pmc Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
    Caroline A Sabin
    Lancet 371:1417-26. 2008
    ..Our aim was to explore whether exposure to such drugs was associated with an excess risk of myocardial infarction in a large, prospective observational cohort of HIV-infected patients...
  31. pmc Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction
    C A Sabin
    Dept of Primary Care and Population Sciences, Royal Free and UC Medical School, Rowland Hill St, London, NW3 2PF, United Kingdom
    Clin Infect Dis 46:1101-10. 2008
    ..We evaluated changes in risk factors for CVD and the use of lipid-lowering therapy in HIV-infected individuals and assessed the impact of any changes on the incidence of myocardial infarction...